The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome

Diabetes Obes Metab. 2024 Jul;26(7):2527-2530. doi: 10.1111/dom.15577. Epub 2024 Apr 1.

Authors

Vladimer Darsalia¹, Ellen Vercalsteren¹, Dimitra Karampatsi¹, Mihaela Oana Romanitan¹, Michael V Mazya^{2

3}, Thomas Nyström¹, Cesare Patrone¹

Affiliations

¹ NeuroCardioMetabol Group, Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, Stockholm, Sweden.
² Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
³ Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.

PMID: 38558509
DOI: 10.1111/dom.15577

No abstract available

Publication types

Editorial

MeSH terms

Diabetes Mellitus / epidemiology
Diabetes Mellitus / therapy
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / therapy
Humans
Hypoglycemic Agents / therapeutic use
Registries*
Stroke* / epidemiology
Stroke* / etiology
Treatment Outcome

Substances

Hypoglycemic Agents

Grants and funding